These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 2165228

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Combination chemotherapy with vincristine, epirubicin and cyclophosphamide in small cell lung carcinoma. Polish Lung Cancer Cooperative Group.
    Jassem J, Karnicka-Młodkowska H, Drozd-Lula M, Strug A, Pilarska-Machowicz A, Michalski A, Kowal E, Moś-Antkowiak R, Zych J.
    Eur J Cancer; 1992; 28(2-3):473-6. PubMed ID: 1317199
    [Abstract] [Full Text] [Related]

  • 3. [EPICO in the treatment of small cell bronchial cancer. 3. Intermediate analysis].
    Drings P, Bülzebruck H, Hruska D, Manke HG, Schuler G.
    Onkologie; 1986 Aug; 9 Suppl 1():14-20. PubMed ID: 3018648
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Adriamycin, cyclophosphamide, vincristine and methotrexate combination chemotherapy of small cell lung cancer].
    Saito H, Kawatsu H, Saka H, Yamamoto M, Takagi E, Tsunekawa H, Kawachi H, Nagura E, Sakai S, Nishiwaki K.
    Gan To Kagaku Ryoho; 1988 Jun; 15(6):1909-13. PubMed ID: 2838000
    [Abstract] [Full Text] [Related]

  • 6. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.
    Hong WK, Nicaise C, Lawson R, Maroun JA, Comis R, Speer J, Luedke D, Hurtubise M, Lanzotti V, Goodlow J.
    J Clin Oncol; 1989 Apr; 7(4):450-6. PubMed ID: 2538577
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cisplatin-VP16 alternating with cyclophosphamide-epirubicin versus cyclophosphamide-epirubicin-vincristine in small cell lung cancer.
    Farris A, Bisail M, Sarobba MG, Sanna G, Scotto T, Valzelli S, Intini C.
    J Chemother; 1993 Oct; 5(5):344-7. PubMed ID: 8106908
    [Abstract] [Full Text] [Related]

  • 11. Combination chemotherapy with cyclophosphamide, epirubicin and etoposide in small cell lung cancer.
    Jassem J, Karnicka-Młodkowska H, Jassem E, Słupek A, Zych J, Wiatr E, Malak S, Moś-Antkowiak R, Szymaczek-Meyer L, Pilarska-Machowicz A.
    Lung Cancer; 1994 Sep; 11(3-4):283-91. PubMed ID: 7812705
    [Abstract] [Full Text] [Related]

  • 12. Sequential high dose-density chemotherapy with two active regimens for advanced small cell lung cancer.
    Vigani A, Pensa F, Vaira F, Bancalari L, Cordani S, Maggiani R, Canessa P, Pronzato P.
    Anticancer Res; 2000 Sep; 20(5C):4015-8. PubMed ID: 11268494
    [Abstract] [Full Text] [Related]

  • 13. Cisplatin and etoposide alternating ifosfamide, vincristine, epirubicin in small cell lung cancer.
    Unsal M, Erturk D.
    Saudi Med J; 2003 Jun; 24(6):628-31. PubMed ID: 12847592
    [Abstract] [Full Text] [Related]

  • 14. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
    Tummarello D, Mari D, Graziano F, Isidori P, Cetto G, Pasini F, Santo A, Cellerino R.
    Cancer; 1997 Dec 15; 80(12):2222-9. PubMed ID: 9404698
    [Abstract] [Full Text] [Related]

  • 15. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
    Wolf M, Havemann K, Holle R, Gropp C, Drings P, Hans K, Schroeder M, Heim M, Dommes M, Mende S.
    J Clin Oncol; 1987 Dec 15; 5(12):1880-9. PubMed ID: 2824710
    [Abstract] [Full Text] [Related]

  • 16. Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer.
    Komaki R, Shin DM, Glisson BS, Fossella FV, Murphy WK, Garden AS, Oswald MJ, Hong WK, Roth JA, Peters LJ.
    Int J Radiat Oncol Biol Phys; 1995 Feb 15; 31(4):807-11. PubMed ID: 7860392
    [Abstract] [Full Text] [Related]

  • 17. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Aamdal S, Norwegian Lung Cancer Study Group.
    Lung Cancer; 2005 May 15; 48(2):251-61. PubMed ID: 15829326
    [Abstract] [Full Text] [Related]

  • 18. Vincristine-cyclophosphamide, the classical two-drug regimen for small-cell lung cancer, evaluated in a randomized study with vindesine.
    Niiranen A, Holsti LR, Salmo M, Holsti P, Mattson K.
    Am J Clin Oncol; 1987 Dec 15; 10(6):507-11. PubMed ID: 2825508
    [Abstract] [Full Text] [Related]

  • 19. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
    Goodman GE, Crowley JJ, Blasko JC, Livingston RB, Beck TM, Demattia MD, Bukowski RM.
    J Clin Oncol; 1990 Jan 15; 8(1):39-47. PubMed ID: 2153194
    [Abstract] [Full Text] [Related]

  • 20. Randomized phase II trial of high-dose 4'-epi-doxorubicin + cyclophosphamide versus high-dose 4'-epi-doxorubicin + cisplatin in previously untreated patients with extensive small cell lung cancer.
    Kánitz E, Kolaric K, Jassem J, Mechl Z, Pawlicki M, Ringwald G, Rolski J, Schoket Z, Vukas D, Kaplan E.
    Oncology; 1992 Jan 15; 49(5):327-32. PubMed ID: 1326734
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.